Product Code: GMDHC11400IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.
Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 7, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Constipation - Overview
- Constipation - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Constipation - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Constipation - Companies Involved in Therapeutics Development
- Allergan Plc
- Ardelyx Inc
- Bausch Health Companies Inc
- Braintree Laboratories Inc
- Dong-A ST Co Ltd
- Enterin Inc
- Inhibikase Therapeutics Inc
- Ironwood Pharmaceuticals Inc
- Kissei Pharmaceutical Co Ltd
- Mallinckrodt Plc
- NGM Biopharmaceuticals Inc
- RaQualia Pharma Inc
- Renexxion LLC
- Sanwa Kagaku Kenkyusho Co Ltd
- Synthetic Biologics Inc
- Yuhan Corp
- Zensun (Shanghai) Sci & Tech Co Ltd
- Constipation - Drug Profiles
- 5-BIOP - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BLI-400 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BLI-801 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DA-6886 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ENT-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IkT-148009 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lactulose 1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- linaclotide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lovastatin MR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lubiprostone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- mizagliflozin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- naronapride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NGM-282 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- plecanatide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RQ-00000010 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tenapanor - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YH-12852 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ZS-06 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Constipation - Dormant Projects
- Constipation - Discontinued Products
- Constipation - Product Development Milestones
- Featured News & Press Releases
- Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
- Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
- Jun 20, 2019: Ironwood and Allergan's LINZESS trial meets primary endpoint
- May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
- May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
- Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
- Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan
- Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored
- Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada
- Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C
- Oct 25, 2018: Synergy Pharmaceuticals provides business update
- Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
- Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
- Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting
- Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
